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Rev-erba, a component of the circadian clock, has also been known as a nuclear receptor that lacks
activation function domain 2, functioning as a ligand-dependent transcriptional repressor.
However, we recently reported that Rev-erba activates connexin43 transcription by forming a
complex with Sp1. Here we show that heme, a REV-ERB ligand, is dispensable for this novel
mechanism and that Rev-erbb, having homologies with Rev-erba, does not activate connexin43,
but competes with the Rev-erba/Sp1. The A/B region of Rev-erba, which is not conserved in Rev-erbb,
is a crucial activating domain, while the ligand binding domain, conserved in Rev-erbb, functions as
a competitor.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Rev-erba and Rev-erbb, initially identiﬁed as orphan nuclear
receptors Nr1d1 and Nr1d2, are also components of the circadian
clock, have important roles in metabolism and cellular differentia-
tion [1–4]. The circadian clock is genetic machinery that generates
autonomous genetic oscillations in systemic organs by coordina-
tion of transcriptional activators (Bmal1 and Clock) and repressors
(Per1–3 and Cry1, 2) that regulate other genes by binding to E
boxesin promoter regions [5,6]. Concurrently, Rev-erba/b and
Rora/b/c have been shown to tune the amplitude and the phase
of the circadian clock, or control transcription of other non-clock
genes, by binding to RORE sites of target genes [1,3,7,8].
Nuclear receptors modulate transcriptional activity by bind-
ing to speciﬁc ligands such as steroid hormones, thyroid hor-
mone, vitamin D and retinoids, and function either as
activators or repressors by recruiting co-activators or co-repres-sors, respectively [9,10]. Rev-erba and Rev-erbb have been con-
sidered to be ligand-dependent transcriptional repressors since
they lack a canonical activation function domain 2 (AF-2)
[11,12] and their repressive effects by recruiting nuclear recep-
tor co-repressor/histone deacetylase 3 depend on their ligand of
heme [13–16].
However, in a sharp contrast to these previous notions, we have
revealed that Rev-erba functions as an activator for connexin43
gene (Cx43) by forming a complex with Sp1 in HEK293T cells and
bladder smooth muscle cells [17]. Importantly, this effect required
proximal Sp1 sites, but no RORE sequences, on the Cx43 promoter.
Sp1 is an Sp/KLF family transcriptional factor that regulates
expression of multiple genes with GC-rich sequences, that is, Sp1
binding sites, on their promoter regions [18,19]. The Sp1-
dependent transactivation of GC-rich promoter sequences is
reported with various nuclear proteins as well as basal transcrip-
tion factors [11]. Interaction between Sp1 and nuclear receptors
are reported with RAR, RXR, ERs and PPAR, which possess common
structures of nuclear receptor domains including an A/B region
(AB), a DNA binding domain (DBD), a hinge region (H) and a ligand
binding domain (LBD) [20–22].
Here, we investigate the detailed mechanism by which
Rev-erba and Sp1 complex to transactivate the Cx43 promoter in
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domains for the process.
2. Methods
Plasmid constructs: The mouse pGL-2-Cx43 promoter–reporter
(pCx43-1686/+165-luc), constructed by Dr. S.J. Lye [23], was a kind
gift from Dr. J. Yao (University of Yamanashi, Yamanashi, Japan).
The pRL-TK (Promega, Madison, WI) were used as a transfection
efﬁcacy control. The Sp1 expression vector, constructed by Dr.
Suske [24] was a kind gift from Dr. Toguchida (Frontier Medical
Sciences, Kyoto University, Kyoto, Japan). The expression vector
of Rev-erba and Rev-erbb was purchased from Open Biosystems
(Huntsville, AL). Site-directed mutagenesis, deletion and addition
of aimed sequences were performed using a mutagenesis basal
kit (Takara) according to the manufacturer’s protocol. These
mutants were all veriﬁed by sequencing.
Promoter–reporter assay: Reporter plasmids with various expres-
sion vectors were transfected into HEK293T cells in 24-well plates
using Fugene6 (Roche) in DMEM with 10% fetal calf serum (FCS)
according to the manufacturer’s protocol. pCx43-luc or pGL2-basic
100 ng and pTK-RL 5 ng were transfected with various amounts of
expression vectors (total 250 ng). Plasmid dosage was kept con-
stant by EGFP-N1 vector. Lysates were harvested 48 h post-trans-
fection, and the luciferase activity was measured using a dual
luciferase assay reagent (Promega). For the hemin treatment, med-
ium was changed to various concentration of hemin in DMEMwith
10% FCS at 24 h after the transfection and kept for 24 h. For SR8278
(Sigma) and GSK4112 (Sigma) treatment, 24 h after the transfection
medium was changed to DMEM with 10% FCS containing 10 lM of
each reagent and incubated for additional 24 h.
Immunoblotting: Preparation of whole-cell lysates from
HEK293T cells, and the immunoblotting procedure were per-
formed as previously described [17,25]. Brieﬂy, cells were lysed
in radio-immunoprecipitation assay (RIPA) buffer containing pro-
tease inhibitors. The protein content of the cell lysates was mea-
sured using the BioRad Protein Assay Kit. Cell lysates were
resolved by sodium dodecyl sulfate polyacrylamide electrophoresis
and transferred to an Immobilon-P membrane (Millipore, Bedford,
MA). The membranes were incubated with antibodies for Sp1
(Millipore, Milford MA, 1:2000), HA (Abcam, 1:8000), DDDDK
(MBL, Aichi, Japan 1:2000), Rev-erba (Cell Signaling Technology
[CST], Beverly, MA, 1:500), Cx43 (Sigma, St Louis, MO, 1:1000),
Bmal1 (Santa Cruz Biotechnology, Santa Cruz, CA 1:200) and GAP-
DH (CST, 1:2000). The Rev-erba antibody of CST (2124) was for 20
amino acids between 200 and 300 from the N terminus, includingFig. 1. Ligand is dispensable for activation by the Rev-erba and Sp1 complex. (A) Additio
Cx43 transcription. N = 3 for each group. (B) Bmal1 expression was decreased by additio
domain (D287–610: RevDLBD) still transactivated the Cx43 promoter. ⁄P < 0.0001 compa
by Dunnett’s post hoc test. +, 125 ng in A and C. Error bars represent S.D. in A and C. For re
erba – Sp1 was set to 1 in C.the H region. After incubation with HRP-conjugated anti-rabbit or
anti-mouse secondary antibodies (Pierce, Rockford, IL), immunore-
active proteins were visualized using a Super Signal West Pico
Chemiluminescent Substrate (Pierce, Rockford, IL).
Co-immunoprecipitation assay: Preparation of nuclear extracts
and co-immunoprecipitation were performed as previously de-
scribed [17]. Brieﬂy nuclear extracts were prepared from HEK293T
cells in 10 cm dishes, transfected with HA-Rev-erba or HA-Rev AB
(3.75 lg), and DDDDK-Sp1 (3.75 lg) expression vectors for 48 h,
using Nuclear Complex Co-IP kit (Active Motif, Carlsbad, CA). The
100 lg of nuclear extracts were incubated with 4 lg of antibodies
for HA and control rabbit IgG (Zymed) in 500 ll of low IP buffer
overnight at 4 C with rotation followed by addition of 30 ll of
Dynabeads Sheep anti-Rabbit IgG (Veritas, Tokyo, Japan) for 1 h.
After washing with low IP buffer, the binding protein was eluted
in 40 ll of RIPA buffer for immunoblotting. The 2 lg of nuclear ex-
tracts were used as input.
Statistical analysis: We used one-way ANOVA followed by
Tukey’s post hoc test for the multiple comparisons or by Dunnett’s
post hoc test for comparing to the control in the promoter–reporter
assay, calculated with SPSS ver.11.0.1Jsoftware (SPSS Inc., Chicago,
IL). A P value <0.05 was accepted as signiﬁcant.3. Results and discussion
3.1. Ligand is dispensable for activation by Rev-erba with Sp1
Firstly, to investigate whether the transactivation of Cx43 pro-
moter by Rev-erba/Sp1 complex is controlled by heme, the ligand
of Rev-erba as a nuclear receptor, we applied various concentra-
tions of heme to the HEK293T cells transfected with Rev-erba/
Sp1. Exogenously applied heme showed little impact on the Cx43
promoter activation (Fig. 1A), while it enhanced the suppressive ef-
fect on the abundance of Bmal1 protein as reported (Fig. 1B)
[13,15]. In addition, SR8278, an antagonist of REV-ERB, was applied
to block the action of endogenous agonist heme, which is always
present in the cells [26]. It also had little effect on the Cx43 pro-
moter activation, which was not inﬂuenced by addition of
GSK4112, an agonist of REV-ERB (Supplementary Fig. S1). Notably,
although the ligand binding domain (LBD) of Rev-erba has been
reported to be crucial for recruiting co-repressors [14,15], a
deletion mutant of LBD of Rev-erba (RevDLBD) still retained trans-
activation activity for the Cx43 promoter (Fig. 1C). In contrast to
the suppressive effect of Rev-erba, the ligand is not considered
to play a signiﬁcant role in the transactivation mechanism.n of hemin, a ligand of Rev-erba, did not increase the effect of Rev-erba and Sp1 on
n of hemin on Rev-erba and Sp1. (C) A mutant with deletion of the ligand binding
red with the control without transfection of Rev-erba by one-way ANOVA followed
lative levels, Rev-erba + Sp1 + hemin 0 lMwas set to 1 in A, and the control as Rev-
Fig. 2. Rev-erbb competes with the Rev-erba and Sp1 complex. (A) Rev-erbb did not transactivate Cx43 promoter. ⁄P < 0.0001 vs. Rev-erbb -, Rev-erba  Sp1 ; P < 0.0001 vs.
Rev-erbb – Rev-erba – Sp1 + by one-way ANOVA followed by Tukey’s post hoc test. N = 3 for each group. +, 125 ng; ++ 250 ng. (B) Rev-erbb competes with Rev-erba and Sp1
complex for transactivation of Cx43 promoter. N = 3. ⁄P < 0.0005 vs. Rev-erbb – Rev - erba – Sp1  or +; P < 0.0001 vs. Rev-erbb – Rev-erba + Sp1 + by one-way ANOVA
followed by Tukey’s post hoc test. +, 50 ng; +++, 150 ng. Error bars represent S.D. in A and B. The controls without Rev-erba and Sp1 were set as 1 in A and B.
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Next, to investigate whether Rev-erbb transactivates the Cx43
promoter in a similar manner as Rev-erba with Sp1, we drove
expression of Rev-erbb in conjunction with a Cx43 promoter–
reporter. However, Rev-erbb scarcely affected the promoter
activity of Cx43 even when co-expressed with Sp1 (Fig. 2A).
Intriguingly, Rev-erbb competed with Rev-erba in the presence
of Sp1 for the transactivation of the Cx43 promoter (Fig. 2B). This
result is completely different from the previous notion that Rev-
erba and Rev-erbb have nearly identical functions in the liver
[27]. These results prompted us to investigate the precise mecha-
nism of Cx43 promoter transactivation by Rev-erba with Sp1.Fig. 3. A/B region dependent activation of the Rev-erba and Sp1 complex. (A) Schematic
binding domain (DBD, 127–203) and hinge regions (H, 204–286) are crucial to activate the
 Sp1; P < 0.0001 compared with Rev-erba – Sp1 + by one-way ANOVA followed by Tu
effects on Cx43 protein expression by immunoblotting. The antibody for Rev-erba (CST), m
the H region, did not recognize RevDH accordingly. Bmal1 is a positive control of DBD and
erba transactivated the Cx43 promoter with Sp1 by itself based on the effect of HA-Rev AB
ANOVA followed by Tukey’s post hoc test. (E) The A/B region of Rev-erbamakes a complex
in HEK293T cells transfected with HA-Rev AB and DDDDK-Sp1. For relative levels, the co3.3. The A/B region of Rev-erba is an activation domain
Alignment comparison of Rev-erba with Rev-erbb disclosed
that they have a different A/B region but a similar DNA binding
domain (DBD), a hinge region (H) and a C terminal region of their
LBD (Supplementary Fig. S2). According to their similarities and
differences, we generated various domain oriented deletion
mutants of Rev-erba to examine the domains responsible for the
activation of Cx43 (Fig. 3A). The promoter–reporter assay revealed
that, a part of the N terminal region of Rev-erba (8–49) and the
LBD were not crucial for the activation of the Cx43 promoter, while
the A/B region, DBD and H region were indispensable (Fig. 3B).
These effects were also conﬁrmed at the protein level by immuno-representations of deletion mutants of Rev-erba. (B) The A/B region (8–126), DNA
Cx43 promoter. +, 125 ng; n = 3 for each group. ⁄P < 0.0001 compared with Rev-erba
key’s post hoc test. (C) Validation of the protein expression of mutant Rev-erba and
ade against the 20 amino acids between 200 and 300 from the N terminus, including
LBD-indispensable negative regulatory effect by Rev-erba. (D) The A/B region of Rev-
(a mutant of Rev-erbawith A/B region only). N = 3 for each. ⁄P < 0.0001 by one-way
with Sp1. DDDDK tagged Sp1 was co-immunoprecipitated using an antibody for HA
ntrols without Rev-erba and Sp1 were set as 1 in B and D.
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wild-type (WT) Rev-erba successfully suppressed Bmal1 protein
expression. Notably, in contrast to the transactivation of the Cx43
promoter, co-transfection of a deletion mutant of the A/B region
(DAB) still had a suppressive effect on Bmal1 expression, while
those with deletions of the DBD, H region or LBD (DDBD, DH and
DLBD) failed to suppress it.
In light of these results, we focused on the A/B region as an acti-
vation domain and generated a DNA construct for expression of
this region alone (HA-Rev AB). Indeed, the HA-Rev AB still transac-
tivated the Cx43 promoter transfected with Sp1 (Fig. 3D) and the
HA-Rev AB was co-immunoprecipitated with Sp1 (Fig. 3E).
3.4. The LBD of Rev-erba is a competition domain
Rev DAB, a mutant Rev-erba without A/B region, not only failed
to activate, but inhibited the transactivation of Cx43 promoterFig. 4. The LBD of Rev-erba competes with the Rev-erba and Sp1 complex. (A) Deletio
transactivate the Cx43 promoter. N = 3 for each. ⁄P < 0.005 compared with Rev-erba – Sp
Tukey’s post hoc test. 1, 37.5 ng; 1.7, 62.5 ng; 2.7, 100 ng; 3.3, 125 ng; 5, 187.5 ng; +, 62.5 n
does a mutant with both the DBD and LBDs. N = 3 for each. ⁄P < 0.005 compared with Re
followed by Tukey’s post hoc test. Error bars represent S.D. in A and B. The controls witho
the transactivation of the Cx43 promoter by Rev-erba complexed with Sp1. The A/B
competitive domain. Rev-erbb, possessing a relatively different A/B region and a simil
promoter.by Rev-erba with Sp1 in a dose dependent manner (Fig. 4A),
indicating that Rev DAB contains a competition domain for
Rev-erba/Sp1 complex to transactivate the Cx43 promoter.
To identify the competition domain of Rev-erba, we assessed
the effect of Rev DH, Rev DBDLBD (a mutant of Rev-erba only with
the DBD and LBD) or Rev DBD (a mutant of Rev-erba only with the
DBD) with Rev-erba/Sp1 (Supplementary Fig. S3). The competition
was observed in Rev DH and Rev DBDLBD but not in Rev DBD,
indicating that not the H region or DBD but the LBD could be the
required domain. Indeed, Rev LBD (a mutant of Rev-erba only with
LBD) competed with the Rev-erba/Sp1 (Fig. 4B). Therefore, the LBD
is involved in the transactivation of the Cx43 promoter by
Rev-erba/Sp1 complex as a potential competition domain.
Thus, different amino acid arrangements in the A/B activation
domain regions of Rev-erba and Rev-erbb may underlie their
differential activation of the Cx43 promoter. Conversely, high
compatibility in LBD between these two Rev-erb subtypes mayn of the A/B region of Rev-erba competed with the Rev-erba and Sp1 complex to
1; P < 0.005 compared with Rev WT 1.7 Sp1 1.7 by one-way ANOVA followed by
g. (B) A mutant of Rev-erbawith only the LBD competes against theWT Rev-erba as
v-erba – Sp1; P < 0.005 compared with Rev WT 1.7 Sp1 1.7 by one-way ANOVA
ut Rev-erba and Sp1 were set as 1 in A and B. (C) A putative mechanistic scheme for
region of Rev-erba interacts with Sp1 as an activation domain and the LBD is a
ar C terminal LBD, does not activate but competes for transactivation of the Cx43
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(Fig. 4C). We should note that this relationship between Rev-erba
and Rev-erbb is similar to the relationship between Estrogen
Receptor (ER) a and ERb. The importance of the A/B region of nu-
clear receptors for associating with Sp1 has also been postulated
for this ER family. Saville et al. reported that the ERa possesses a
transactivation function, but ERb does not, while a chimeric ERa/
b, possessing the A/B region of ERa and other domains of ERb, also
has a transactivation function on a 17-beta Estradiol 2-responsive
construct containing a GC-rich promoter [28]. ERa and ERb are also
competitive on the Sp1 site of the promoter [28]. Li et al. demon-
strated that amino acids 67–139 of ERa, a part of the A/B region,
were sufﬁcient for the transactivation by ERa/Sp1 [29].
The physiological implication of this novel competitive role for
Rev-erbb is unclear. Rev-erbb is also a component of the circadian
clock [27,30] and oscillates in the urinary bladder (Supplementary
Fig. S4), thus one could speculate that Rev-erbb tunes the circadian
expression of Cx43 by competing with Rev-erba. Because the peak
expression of Rev-erbb is 3.6 h later than Rev-erba, followed by
Cx43 (Supplementary Fig. S4) in the urinary bladder, Rev-erbb
may contribute to decrease the transactivation of Cx43 after the
peak point. Since the present study relies to a large extent on over-
expression and reporter assays, physiological relevance and func-
tional signiﬁcance of the ﬁndings still remains to be determined.
As other limitation of the present study, we showed the speciﬁc
role of Rev-erba domains for transactivation of the Cx43 promoter,
but not the speciﬁc amino acid sequence required for the activation
by Rev-erba/Sp1 complex. The molecular structure of the complex,
including the detailed interaction with Sp1 and other co-activators
and/or co-repressors, which may also induce differences in effect of
Rev-erba/b [31–34], remains to be investigated to elucidate the en-
tire mechanism of this novel transcription complex.
In summary, the present study shows that heme as the ligand is
dispensable for transactivation of the Cx43 promoter by Rev-erba
with Sp1, and that the A/B region of Rev-erba functions as an acti-
vation domain, while the LBD of Rev-erba is a competition domain.
This mechanism may underlie the competitive effect by Rev-erbb
on the transactivation. These ﬁndings provide a new insight into
interaction between the clock regulator/nuclear receptors and Sp1.
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